MiNK Therapeutics, Inc. Net Income
MiNK Therapeutics, Inc. (INKT) reported Net Income of -$3.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-13
- MiNK Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$3.13M.
- MiNK Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$2.74M.
- MiNK Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$2.60M.
- MiNK Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$2.89M.
- MiNK Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2025 was -$12.49M.
- MiNK Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2024 was -$10.78M.
- MiNK Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2023 was -$22.46M.
- MiNK Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$27.99M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.13M 10-Q · filed 2026-08-13 | -$5.87M 10-Q · filed 2026-08-13 | -$8.47M derived: sum of 3 quarters · filed 2026-08-13 | -$11.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$2.74M 10-Q · filed 2026-08-13 | -$5.34M derived: sum of 2 quarters · filed 2026-08-13 | -$8.23M derived: sum of 3 quarters · filed 2026-08-13 | -$12.47M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$5.49M derived: sum of 2 quarters · filed 2026-03-31 | -$9.73M derived: sum of 3 quarters · filed 2026-08-13 | -$12.49M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$2.89M 10-Q · filed 2025-11-14 | -$7.13M derived: sum of 2 quarters · filed 2026-08-13 | -$9.89M 10-Q · filed 2025-11-14 | -$12.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$4.24M 10-Q · filed 2026-08-13 | -$7.00M 10-Q · filed 2026-08-13 | -$9.47M derived: sum of 3 quarters · filed 2026-08-13 | -$11.27M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$2.77M 10-Q · filed 2026-08-13 | -$5.23M derived: sum of 2 quarters · filed 2026-08-13 | -$7.04M derived: sum of 3 quarters · filed 2026-08-13 | -$9.74M derived: sum of 4 quarters · filed 2026-08-13 |
| 2024-12-31 | -$2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.27M derived: sum of 2 quarters · filed 2026-03-31 | -$6.97M derived: sum of 3 quarters · filed 2026-03-31 | -$10.78M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$1.81M 10-Q · filed 2025-11-14 | -$4.51M derived: sum of 2 quarters · filed 2025-11-14 | -$8.32M 10-Q · filed 2025-11-14 | -$13.78M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$2.70M 10-Q · filed 2025-11-14 | -$6.52M 10-Q · filed 2025-08-14 | -$11.97M derived: sum of 3 quarters · filed 2025-11-14 | -$17.09M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-03-31 | -$3.81M 10-Q · filed 2025-11-14 | -$9.27M derived: sum of 2 quarters · filed 2025-11-14 | -$14.39M derived: sum of 3 quarters · filed 2025-11-14 | -$20.59M derived: sum of 4 quarters · filed 2025-11-14 |
| 2023-12-31 | -$5.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$10.57M derived: sum of 2 quarters · filed 2025-03-18 | -$16.77M derived: sum of 3 quarters · filed 2025-03-18 | -$22.46M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$5.12M 10-Q · filed 2024-11-14 | -$11.31M derived: sum of 2 quarters · filed 2024-11-14 | -$17.00M 10-Q · filed 2024-11-14 | -$24.77M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$6.20M 10-Q · filed 2024-11-14 | -$11.88M 10-Q · filed 2024-08-13 | -$19.65M derived: sum of 3 quarters · filed 2024-11-14 | -$25.98M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-03-31 | -$5.69M 10-Q · filed 2024-11-14 | -$13.46M derived: sum of 2 quarters · filed 2024-11-14 | -$19.79M derived: sum of 3 quarters · filed 2024-11-14 | -$25.90M derived: sum of 4 quarters · filed 2024-11-14 |
| 2022-12-31 | -$7.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$14.10M derived: sum of 2 quarters · filed 2024-03-21 | -$20.21M derived: sum of 3 quarters · filed 2024-03-21 | -$27.99M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$6.33M 10-Q · filed 2023-11-14 | -$12.44M derived: sum of 2 quarters · filed 2023-11-14 | -$20.22M 10-Q · filed 2023-11-14 | -$25.99M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$6.11M 10-Q · filed 2023-11-14 | -$13.89M 10-Q · filed 2023-08-10 | -$19.65M derived: sum of 3 quarters · filed 2023-11-14 | -$33.92M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-03-31 | -$7.78M 10-Q · filed 2023-11-14 | -$13.54M derived: sum of 2 quarters · filed 2023-11-14 | -$27.81M derived: sum of 3 quarters · filed 2023-11-14 | -$34.14M derived: sum of 4 quarters · filed 2023-11-14 |
| 2021-12-31 | -$5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$20.03M derived: sum of 2 quarters · filed 2023-03-24 | -$26.37M derived: sum of 3 quarters · filed 2023-03-24 | -$30.21M 10-K · filed 2023-03-24 |
| 2021-09-30 | -$14.27M 10-Q · filed 2022-11-03 | -$20.60M derived: sum of 2 quarters · filed 2022-11-03 | -$24.45M 10-Q · filed 2022-11-03 | -$25.98M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$6.34M 10-Q · filed 2022-11-03 | -$10.18M 10-Q · filed 2022-08-15 | -$11.72M derived: sum of 3 quarters · filed 2022-11-03 | -$17.76M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-03-31 | -$3.85M 10-Q · filed 2022-11-03 | -$5.38M derived: sum of 2 quarters · filed 2022-11-03 | -$11.42M derived: sum of 3 quarters · filed 2022-11-03 | -$15.69M derived: sum of 4 quarters · filed 2022-11-03 |
| 2020-12-31 | -$1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$7.58M derived: sum of 2 quarters · filed 2022-03-18 | -$11.85M derived: sum of 3 quarters · filed 2022-03-18 | -$16.24M 10-K · filed 2022-03-18 |
| 2020-09-30 | -$6.04M 10-Q · filed 2021-11-29 | -$10.31M derived: sum of 2 quarters · filed 2021-11-29 | -$14.70M 10-Q · filed 2021-11-29 | |
| 2020-06-30 | -$4.27M 10-Q · filed 2021-11-29 | -$8.66M derived: sum of 2 quarters · filed 2021-11-29 | ||
| 2020-03-31 | -$4.39M 10-Q · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |